The 10-member Subject Expert Committee (SEC) of India's Central Drug Standard Control Organisation (CDSCO) today (1 January) approved emergency use authorisation of the Oxford-AstraZeneca coronavirus vaccine 'Covishield'.
As per reports the SEC recommended in favour of the emergency use authorisation to the DCGI subject to certain conditions. The vaccine has been developed by scientists at the UK's Oxford University and is produced by AstraZeneca.
The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech for its Covaxin.
Once the vaccines are cleared by the committee, the application will be sent to Drugs Controller General of India (DCGI) V G Somani for final approval.
The vaccine doses may start getting transported to states from tomorrow.
The Serum Institute of India which locally manufactures the vaccine has rolled out 50 million doses of Covishield - majority of which will be used in India.
The overall efficacy of this vaccine is pegged at 70.4 per cent and can be stored in domestic refrigeration. It is likely to be priced well below Rs 1,000 for the two mandatory doses.
As per reports, similar approval may also be given to the second vaccine which has been jointly developed by Indian Council of Medical Research (ICMR) and Bharat Biotech.
With Inputs From IANS
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.